If you have been reading about GLP-1 analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-02. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Protein sequencing is the practical process of determining the amino acid sequence of all or part of a protein or peptide. This may serve to identify the protein or characterize its post-translational modifications. Typically, partial sequencing of a protein provides sufficient information (one or more sequence tags) to identify it with reference to databases of protein sequences derived from the conceptual translation of genes. The two major direct methods of protein sequencing are mass spectrometry and Edman degradation using a protein sequenator (sequencer). Mass spectrometry methods are now the most widely used for protein sequencing and identification but Edman degradation remains a valuable tool for characterizing a protein's N-terminus.
Iodine absorbed by the body is almost completely stored in the thyroid gland and has a biological half-life of about 120 days. If the iodine is radioactive (131I), it can irradiate and damage the thyroid gland in high doses during this time. Because the thyroid gland can only absorb a limited amount of iodine, prophylactic administration of non-radioactive iodine may result in iodine blockade. Potassium iodide in tablet form (colloquially known as "iodine tablets") reduces the uptake of radioactive iodine into the thyroid by a factor of 90 or more, thus acting as a radioprotector. All other radiation damage remains unaffected by taking iodine tablets. In Germany, the Potassium Iodide Ordinance (KIV) was enacted in 2003 to ensure "the supply of the population with potassium iodide-containing medicines in the event of radiological incidents". § 1 kiv (in German) Potassium iodide is usually stored in communities near nuclear facilities for distribution to the population in the event of a disaster. People over the age of 45 should not take iodine tablets because the risk of side effects is higher than the risk of developing thyroid cancer. In Switzerland, as a precautionary measure, tablets have been distributed every five years since 2004 to the population living within 20 km of nuclear power plants (from 2014, 50 km). In Austria, large stocks of iodine tablets have been kept in pharmacies, kindergartens, schools, the army and the federal reserve since 2002.
== ACTH receptors outside the adrenal gland == As indicated above, ACTH is a cleavage product of the pro-hormone, proopiomelanocortin (POMC), which also produces other hormones including α-MSH that stimulates the production of melanin. A family of related receptors mediates the actions of these hormones, the MCR, or melanocortin receptor family. These are mainly not associated with the pituitary-adrenal axis. MC2R is the ACTH receptor. While it has a crucial function in regulating the adrenal glands, it is also expressed elsewhere in the body, specifically in the osteoblast, which is responsible for making new bone, a continual and highly regulated process in the bodies of air-breathing vertebrates. The functional expression of MC2R on the osteoblast was discovered by Isales et alia in 2005. Since that time, it has been demonstrated that the response of bone forming cells to ACTH includes production of VEGF, as it does in the adrenal. This response might be important in maintaining osteoblast survival under some conditions. If this is physiologically important, it probably functions in conditions with short-period or intermittent ACTH signaling, since with continual exposure of osteoblasts to ACTH, the effect was lost in a few hours.
=== Availability === Etifoxine has been marketed in 53 countries as of 2022. Some of the countries in which etifoxine has been marketed include Argentina, Bulgaria, Chile, France, Luxembourg, Malta, Romania, South Africa, Thailand and Ukraine. Etifoxine is not approved for use by the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) of the European Union, and hence is not marketed in these regions. However, etifoxine is marketed in five European Union member states (France, Bulgaria, Luxembourg, Malta, Romania) and Ukraine
=== Analogues === In addition to deupsilocin, Helus Pharma has also patented other deuterated psilocin isotopologues. Other deuterated drugs related to deupsilocin include the deuterated dimethyltryptamine (DMT) isotopologues deudimethyltryptamine (HLP004; CYB004; DMT-d10; deudimethyltryptamine) and SPL028 (D2-DMT) and the deuterated phenethylamine HLP005 (CYB005).
Sources: en.wikipedia.org
Adrenocorticotropic hormone release is triggered by corticotropin-releasing hormone and inhibited by rising glucocorticoid levels. The gonadotropins—follicle-stimulating hormone and luteinizing hormone regulate the functions of the gonads in both sexes. Follicle-stimulating hormone stimulates sex cell production; luteinizing hormone stimulates gonadal hormone production. Gonadotropin levels rise in response to gonadotropin-releasing hormone. Negative feedback of gonadal hormones inhibits gonadotropin release. Prolactin promotes milk production in human females. Its secretion is prompted by prolactin-releasing hormone and inhibited by prolactin-inhibiting hormone. The intermediate lobe of the pituitary gland secretes only one enzyme that is melanocyte stimulating hormone. It is linked with the formation of the black pigment in our skin called melanin. The neurohypophysis stores and releases two hypothalamic hormones:
Some reach back even further as Wisconsin School historian Walter LaFeber in his study America, Russia, and the Cold War, first published in 1972, argued that the Cold War had its origins in 19th century conflicts between Russia and the United States over the opening of East Asia to American trade, markets and influence. LaFeber argued that the United States commitment at the close of World War II to ensuring a world in which every state was open to American influence and trade, underpinned many of the conflicts that triggered the beginning of the Cold War. Starting with Gar Alperovitz in his influential Atomic Diplomacy: Hiroshima and Potsdam (1965), revisionists have focused on the United States decision to use atomic weapons against Hiroshima and Nagasaki during the last days of World War II. In their belief, the nuclear bombing of Nagasaki and Hiroshima in effect started the Cold War. According to Alperovitz, the bombs were used not against an already-defeated Japan to win the war, but to intimidate the Soviets by signaling that the United States would use nuclear weapons to stop Soviet expansion, though they failed to do so. New Left historians Joyce and Gabriel Kolko's The Limits of Power: The World and U.S. Foreign Policy, 1945–1954 (1972) has also received considerable attention in the historiography on the Cold War. The Kolkos argued American policy was both reflexively anticommunist and counterrevolutionary.
==== Metabolism ==== 2C-B appears to undergo substantial first-pass metabolism. It has been shown to be metabolized by liver hepatocytes, resulting in deamination and demethylation that produces several products. Oxidative deamination results in the 2-(4-bromo-2,5-dimethoxyphenyl)ethanol (BDMPE) and 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) metabolites. Additionally, 4-bromo-2,5-dimethoxybenzoic acid (BDMBA) can be produced by oxidative deamination. Further metabolism of BDMPE and BDMPAA may occur by demethylation. Alternatively, the later metabolites can be generated by demethylation of 2C-B followed by oxidative deamination. Deamination of 2C-B is mediated by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. There is species differentiation in the metabolism of 2C-B. Mice hepatocytes produce 4-bromo-2,5-dimethoxyphenol (BDMP), a previously unknown metabolite. Meanwhile, human, monkey, and rabbit hepatocytes produce 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE), but dog, rat, and mouse hepatocytes do not. 2C-B's metabolites BDMPAA and 4-bromo-2-hydroxy-5-methoxyphenylacetic acid (B-2-HMPAA) in humans occur at peak concentrations 280-fold and 17-fold higher than those of 2C-B with oral administration of 2C-B, respectively. Another known metabolite of 2C-B is 2-OH-2C-B (2-DM-2C-B; B-2-HMPEA). This compound is active and has similarly potency as a serotonin 5-HT2A receptor agonist as 2C-B itself in vitro.
The ionizing radiation emitted by radium bromide excites nitrogen molecules in the air, making it glow. The alpha particles emitted by radium quickly gain two electrons to become neutral helium, which builds up inside and weakens radium bromide crystals. This effect sometimes causes the crystals to break or even explode. Radium nitrate (Ra(NO3)2) is a white compound that can be made by dissolving radium carbonate in nitric acid. As the concentration of nitric acid increases, the solubility of radium nitrate decreases, an important property for the chemical purification of radium. Radium forms much the same insoluble salts as its lighter congener barium: it forms the insoluble sulfate (RaSO4, the most insoluble known sulfate), chromate (RaCrO4), carbonate (RaCO3), iodate (Ra(IO3)2), tetrafluoroberyllate (RaBeF4), and nitrate (Ra(NO3)2). With the exception of the carbonate, all of these are less soluble in water than the corresponding barium salts, but they are all isostructural to their barium counterparts. Additionally, radium phosphate, oxalate, and sulfite are probably also insoluble, as they coprecipitate with the corresponding insoluble barium salts. The great insolubility of radium sulfate (at 20 °C, only 2.1 mg will dissolve in 1 kg of water) means that it is one of the less biologically dangerous radium compounds. The large ionic radius of Ra2+ (148 pm) results in weak ability to form coordination complexes and poor extraction of radium from aqueous solutions when not at high pH.
Trophic hormones are hormones of the anterior lobe of the pituitary. These hormones affect growth, function, or nutrition of other endocrine cells. Trophic hormones can be found in body systems including the endocrine, gastrointestinal, urinary, and nervous systems. The term trophic is from Ancient Greek τροφικός (trophikós) meaning "pertaining to food or nourishment", here used to mean "growth"; this is the same origin as atrophy. This should not be confused with tropic, as in the similar-sounding tropic hormone – the words and concepts are both unrelated. An example of this is thyroid-stimulating hormone stimulating the thyroid; excess thyroid-stimulating hormone can create a goitre. Trophic hormones from the anterior pituitary include:
Sources: en.wikipedia.org
==== Road ==== The post road built by Thomas Telford from London strengthened Holyhead's position as the port from which the Royal Mail was dispatched to and from Dublin on the Mail coach. The A5 terminates at Admiralty Arch (1822–24), which was designed by Thomas Harrison to commemorate a visit by King George IV in 1821 en route to Ireland and marked the zenith of Irish Mail coach operations. Holy Island and Anglesey are separated by the Cymyran Strait which used to be crossed on the Four Mile Bridge; so called, because the bridge was 4 miles (6 kilometres) from Holyhead on the old turnpike.
=== Pseudobulbar affect === Pseudobulbar affect (PBA) is a condition involving episodic uncontrollable laughter or crying. PBA mostly occurs in people with neurological injuries affecting how the brain controls emotions. Scientists believe PBA results from prefrontal cortex damage. PBA often involves crying. Hence, PBA is mistakable for depression. But PBA is neurological; depression is psychological. Patients with PBA do not experience typical depression symptoms like sleep disturbances or appetite loss.
== Examples == Strategies for improving platinum-based anticancer drugs usually involve changes in the neutral spectator ligands, changes in the nature of the anions (halides vs various carboxylates), or changes in the oxidation state of the metal (Pt(II) vs Pt(IV)). Nanotechnology has been explored to deliver platinum more efficiently in the case of lipoplatin, which is introduced into the tumor sites thereby reducing the chance of toxicity. Cisplatin was the first to be developed. Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%. This application of cisplatin was developed by pediatric oncologist Roger Packer in the early 1980s.
Cl−S−C(=O)−Cl + CH3CH2−O−C(=S)−NH−R → S2(CO)2NR + HCl + CH3CH2Cl Alcohols and amines react at the acyl chloride position to form alkoxycarbonylsulfenyl chlorides and carbamoylsulfenyl chlorides. Thiols selectively react at the sulfenyl chloride position to form S-alkylchlorocarbonyl disulfides:ROH + Cl–S–C(=O)–Cl → Cl–S–C(=O)–OR + HCl RNH2 + Cl–S–C(=O)–Cl → Cl–S–C(=O)–NHR + HCl
μ-Opioid receptor (MOR): extremely high affinity partial agonist: at low doses, the MOR-mediated effects of buprenorphine are comparable to those of other narcotics, but these effects reach a "ceiling" as the receptor population is saturated. This behavior is responsible for several unique properties: buprenorphine greatly reduces the effect of most other MOR agonists, can cause precipitated withdrawal when used in actively opioid dependent persons, and has a lower incidence of respiratory depression relative to full MOR agonists. κ-Opioid receptor (KOR): High affinity antagonist/weak partial agonist —this activity is hypothesized to underlie some of the effects of buprenorphine on mood disorders and addiction. δ-Opioid receptor (DOR): High affinity antagonist Nociceptin receptor (NOP, ORL-1): Weak affinity, very weak partial agonist In simplified terms, buprenorphine can essentially be thought of as a nonselective, mixed agonist–antagonist opioid receptor modulator, acting as an unusually high affinity, weak partial agonist of the MOR, a high affinity antagonist of the KOR and DOR, and a relatively low affinity, very weak partial agonist of the ORL-1/NOP. Although buprenorphine is a partial agonist of the MOR, human studies have found that it acts like a full agonist with respect to analgesia in opioid-intolerant individuals. Conversely, buprenorphine behaves like a partial agonist of the MOR with respect to respiratory depression. Buprenorphine is also known to have high binding affinity with antagonistic activity at the putative ε-opioid receptor.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.